1. Home
  2. CURR vs CRVO Comparison

CURR vs CRVO Comparison

Compare CURR & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CURR
  • CRVO
  • Stock Information
  • Founded
  • CURR 2013
  • CRVO 2001
  • Country
  • CURR Singapore
  • CRVO United States
  • Employees
  • CURR N/A
  • CRVO N/A
  • Industry
  • CURR Business Services
  • CRVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • CURR Consumer Discretionary
  • CRVO Health Care
  • Exchange
  • CURR Nasdaq
  • CRVO Nasdaq
  • Market Cap
  • CURR 89.8M
  • CRVO 98.3M
  • IPO Year
  • CURR N/A
  • CRVO N/A
  • Fundamental
  • Price
  • CURR $1.34
  • CRVO $1.94
  • Analyst Decision
  • CURR
  • CRVO Buy
  • Analyst Count
  • CURR 0
  • CRVO 8
  • Target Price
  • CURR N/A
  • CRVO $38.75
  • AVG Volume (30 Days)
  • CURR 10.5K
  • CRVO 922.0K
  • Earning Date
  • CURR 02-11-2025
  • CRVO 11-12-2024
  • Dividend Yield
  • CURR N/A
  • CRVO N/A
  • EPS Growth
  • CURR N/A
  • CRVO N/A
  • EPS
  • CURR N/A
  • CRVO N/A
  • Revenue
  • CURR $55,500,917.00
  • CRVO $10,066,550.00
  • Revenue This Year
  • CURR N/A
  • CRVO $34.17
  • Revenue Next Year
  • CURR N/A
  • CRVO N/A
  • P/E Ratio
  • CURR N/A
  • CRVO N/A
  • Revenue Growth
  • CURR N/A
  • CRVO 116.29
  • 52 Week Low
  • CURR $1.20
  • CRVO $1.80
  • 52 Week High
  • CURR $5.74
  • CRVO $26.38
  • Technical
  • Relative Strength Index (RSI)
  • CURR N/A
  • CRVO 24.36
  • Support Level
  • CURR N/A
  • CRVO $1.81
  • Resistance Level
  • CURR N/A
  • CRVO $2.10
  • Average True Range (ATR)
  • CURR 0.00
  • CRVO 1.59
  • MACD
  • CURR 0.00
  • CRVO -0.74
  • Stochastic Oscillator
  • CURR 0.00
  • CRVO 1.11

About CURR Currenc Group Inc. Ordinary Shares

Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants worldwide, delivering frictionless interoperable real-time fund transfers and instant messaging.

About CRVO CervoMed Inc.

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Share on Social Networks: